



SelectImmune Pharma will implement reporting in English

SelectImmune Pharma is extending its presence on the international Pharmaceutical arena, where research & development as well as clinical study results and strategic partnerships are typically reported in English. Hence the company Board of Directors has decided to change the company reporting language to English from 2021/2022 and onwards.

The web site will feature parallel documents in English and Swedish, including Annual and quarterly reports and press releases.

For more information, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

Ann Gidner

CEO SelectImmune Pharma AB

Phone: +46 768 17 14 14

E-mail: ann.gidner@selectimmune.com

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UTI) are one of the world's most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.